145 related articles for article (PubMed ID: 38227031)
21. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
22. Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.
Mandelblatt JS; Near AM; Miglioretti DL; Munoz D; Sprague BL; Trentham-Dietz A; Gangnon R; Kurian AW; Weedon-Fekjaer H; Cronin KA; Plevritis SK
Med Decis Making; 2018 Apr; 38(1_suppl):9S-23S. PubMed ID: 29554466
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
[TBL] [Abstract][Full Text] [Related]
24. Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model.
Schechter CB; Near AM; Jayasekera J; Chandler Y; Mandelblatt JS
Med Decis Making; 2018 Apr; 38(1_suppl):66S-77S. PubMed ID: 29554462
[TBL] [Abstract][Full Text] [Related]
25. Relationship of established risk factors with breast cancer subtypes.
McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model.
Birnbaum J; Gadi VK; Markowitz E; Etzioni R
Ann Intern Med; 2016 Feb; 164(4):236-43. PubMed ID: 26756332
[TBL] [Abstract][Full Text] [Related]
27. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
28. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer deaths averted over 3 decades.
Hendrick RE; Baker JA; Helvie MA
Cancer; 2019 May; 125(9):1482-1488. PubMed ID: 30740647
[TBL] [Abstract][Full Text] [Related]
30. Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.
Morrell S; Taylor R; Roder D; Robson B; Gregory M; Craig K
Br J Cancer; 2017 Mar; 116(6):828-839. PubMed ID: 28183141
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
[TBL] [Abstract][Full Text] [Related]
32. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai.
Mittra I; Mishra GA; Dikshit RP; Gupta S; Kulkarni VY; Shaikh HKA; Shastri SS; Hawaldar R; Gupta S; Pramesh CS; Badwe RA
BMJ; 2021 Feb; 372():n256. PubMed ID: 33627312
[TBL] [Abstract][Full Text] [Related]
33. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
34. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
[TBL] [Abstract][Full Text] [Related]
36. Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer.
Nguyen D; Yu J; Reinhold WC; Yang SX
JAMA Netw Open; 2020 Jul; 3(7):e207213. PubMed ID: 32644137
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
Tarantino P; Jin Q; Tayob N; Jeselsohn RM; Schnitt SJ; Vincuilla J; Parker T; Tyekucheva S; Li T; Lin NU; Hughes ME; Weiss AC; King TA; Mittendorf EA; Curigliano G; Tolaney SM
JAMA Oncol; 2022 Aug; 8(8):1177-1183. PubMed ID: 35737367
[TBL] [Abstract][Full Text] [Related]
38. Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice.
Berg T; Jensen MB; Rossing M; Axelsen CT; Kümler I; Søndergaard L; Vogsen M; Knoop AS; Ejlertsen B
Acta Oncol; 2024 May; 63():277-287. PubMed ID: 38711384
[TBL] [Abstract][Full Text] [Related]
39. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
40. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
Qi G; Zhang X; Gai X; Yan X
PeerJ; 2024; 12():e17377. PubMed ID: 38766488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
